FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129609847> ?p ?o ?g. }

• W3129609847 endingPage "1601" @default.
• W3129609847 startingPage "1596" @default.
• W3129609847 abstract "Antibodies targeting tumor necrosis factor-alpha [TNF-alpha] are a mainstay in the treatment of inflammatory bowel disease. However, they fail to demonstrate efficacy in a considerable proportion of patients. On the other hand, glycosylation of antibodies might influence not only their immunogenicity but also their structure and function. We investigated whether specific glycosylation patterns of the Fc-fragment would affect the immunogenicity of anti-TNF-alpha antibody in monocyte-derived dendritic cells.The effect of a specific Fc-glycosylation pattern on antibody uptake by monocyte-derived dendritic cells [mo-DCs] and how this process shapes the immunologic profile of mo-DCs was investigated. Three N-glycoforms of the anti-TNF-alpha antibody adalimumab, that differed in the content of fucose or sialic acid, were tested: [1] mock treated Humira, abbreviated 'Fuc-G0', where the N-glycan mainly consist of fucose and N-acetylglucosamine [GlcNAc], without sialic acid; [2] 'Fuc-G2S1/G2S2' with fucose and alpha 2,6 linked sialic acid; and [3] 'G2S1/G2S2' with alpha 2,6 linked sialic acid, without fucose.Our data demonstrated that neither fucosylation nor sialylation of anti-TNF-Abs [Fuc-G0, FucG2S1/G2S2, G2S1/G2S2] influence their uptake by mo-DCs. Additionally, none of the differentially glycosylated antibodies altered CD80, CD86, CD273, CD274 levels on mo-DCs stimulated in with lipopolysaccharide in the presence of antibodies. Next, we evaluated the levels of cytokines in the supernatant of mo-DCs stimulated with lipopolysaccharide in the presence of Fuc-G0, Fuc-G2S1/G2S2 or G2S1/G2S2-glycosylated anti-TNF antibodies. Only IL-2 and IL-17 levels were downregulated, and IL-5 production was upregulated by uptake of Fuc-G0 antibodies, as compared to control without antibodies.The specific modification in the Fc-glycosylation pattern of anti-TNF-alpha Abs does not affect their immunogenicity under the tested conditions. As this study was limited to mo-DCs, further investigation is required to clarify whether Ab uptake into mo-DCs might change the immunological profile of T- and B-cells, in order to ultimately reduce the formation of anti-drug antibodies and to improve the patient care." @default.
• W3129609847 created "2021-03-01" @default.
• W3129609847 creator A5004285963 @default.
• W3129609847 creator A5041403658 @default.
• W3129609847 creator A5044704932 @default.
• W3129609847 creator A5049679213 @default.
• W3129609847 creator A5058227847 @default.
• W3129609847 creator A5061735145 @default.
• W3129609847 creator A5064915362 @default.
• W3129609847 creator A5073764687 @default.
• W3129609847 creator A5083678147 @default.
• W3129609847 creator A5083860339 @default.
• W3129609847 date "2021-02-26" @default.
• W3129609847 modified "2023-09-25" @default.
• W3129609847 title "Fucosylation and Sialylation of Fc-Fragment of anti-Tumour Necrosis Factor Alpha Antibodies do not Influence Their Immunogenicity in Monocyte-Derived Dendritic Cells" @default.
• W3129609847 cites W1898757929 @default.
• W3129609847 cites W1977978637 @default.
• W3129609847 cites W1979767710 @default.
• W3129609847 cites W1985075809 @default.
• W3129609847 cites W1987913986 @default.
• W3129609847 cites W1997999969 @default.
• W3129609847 cites W2001157494 @default.
• W3129609847 cites W2037117519 @default.
• W3129609847 cites W2051666192 @default.
• W3129609847 cites W2071476490 @default.
• W3129609847 cites W2084136419 @default.
• W3129609847 cites W2091948625 @default.
• W3129609847 cites W2149065814 @default.
• W3129609847 cites W2290698646 @default.
• W3129609847 cites W2600926306 @default.
• W3129609847 cites W2764071025 @default.
• W3129609847 cites W2766842037 @default.
• W3129609847 cites W2806365218 @default.
• W3129609847 cites W2900652055 @default.
• W3129609847 doi "https://doi.org/10.1093/ecco-jcc/jjab038" @default.
• W3129609847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33631789" @default.
• W3129609847 hasPublicationYear "2021" @default.
• W3129609847 type Work @default.
• W3129609847 sameAs 3129609847 @default.
• W3129609847 citedByCount "1" @default.
• W3129609847 countsByYear W31296098472022 @default.
• W3129609847 crossrefType "journal-article" @default.
• W3129609847 hasAuthorship W3129609847A5004285963 @default.
• W3129609847 hasAuthorship W3129609847A5041403658 @default.
• W3129609847 hasAuthorship W3129609847A5044704932 @default.
• W3129609847 hasAuthorship W3129609847A5049679213 @default.
• W3129609847 hasAuthorship W3129609847A5058227847 @default.
• W3129609847 hasAuthorship W3129609847A5061735145 @default.
• W3129609847 hasAuthorship W3129609847A5064915362 @default.
• W3129609847 hasAuthorship W3129609847A5073764687 @default.
• W3129609847 hasAuthorship W3129609847A5083678147 @default.
• W3129609847 hasAuthorship W3129609847A5083860339 @default.
• W3129609847 hasConcept C108625454 @default.
• W3129609847 hasConcept C153911025 @default.
• W3129609847 hasConcept C159654299 @default.
• W3129609847 hasConcept C17991360 @default.
• W3129609847 hasConcept C185592680 @default.
• W3129609847 hasConcept C203014093 @default.
• W3129609847 hasConcept C206212055 @default.
• W3129609847 hasConcept C2776841590 @default.
• W3129609847 hasConcept C2777313579 @default.
• W3129609847 hasConcept C2778754761 @default.
• W3129609847 hasConcept C2779212266 @default.
• W3129609847 hasConcept C2780115458 @default.
• W3129609847 hasConcept C2780868878 @default.
• W3129609847 hasConcept C2781184567 @default.
• W3129609847 hasConcept C55493867 @default.
• W3129609847 hasConcept C86803240 @default.
• W3129609847 hasConceptScore W3129609847C108625454 @default.
• W3129609847 hasConceptScore W3129609847C153911025 @default.
• W3129609847 hasConceptScore W3129609847C159654299 @default.
• W3129609847 hasConceptScore W3129609847C17991360 @default.
• W3129609847 hasConceptScore W3129609847C185592680 @default.
• W3129609847 hasConceptScore W3129609847C203014093 @default.
• W3129609847 hasConceptScore W3129609847C206212055 @default.
• W3129609847 hasConceptScore W3129609847C2776841590 @default.
• W3129609847 hasConceptScore W3129609847C2777313579 @default.
• W3129609847 hasConceptScore W3129609847C2778754761 @default.
• W3129609847 hasConceptScore W3129609847C2779212266 @default.
• W3129609847 hasConceptScore W3129609847C2780115458 @default.
• W3129609847 hasConceptScore W3129609847C2780868878 @default.
• W3129609847 hasConceptScore W3129609847C2781184567 @default.
• W3129609847 hasConceptScore W3129609847C55493867 @default.
• W3129609847 hasConceptScore W3129609847C86803240 @default.
• W3129609847 hasIssue "9" @default.
• W3129609847 hasLocation W31296098471 @default.
• W3129609847 hasLocation W31296098472 @default.
• W3129609847 hasOpenAccess W3129609847 @default.
• W3129609847 hasPrimaryLocation W31296098471 @default.
• W3129609847 hasRelatedWork W1999975887 @default.
• W3129609847 hasRelatedWork W2149603938 @default.
• W3129609847 hasRelatedWork W2320367064 @default.
• W3129609847 hasRelatedWork W2494280070 @default.
• W3129609847 hasRelatedWork W2556080091 @default.
• W3129609847 hasRelatedWork W2912864811 @default.
• W3129609847 hasRelatedWork W3011884632 @default.
• W3129609847 hasRelatedWork W3012465734 @default.
• W3129609847 hasRelatedWork W3176709039 @default.

• next